1. Home
  2. FNF vs UTHR Comparison

FNF vs UTHR Comparison

Compare FNF & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FNF
  • UTHR
  • Stock Information
  • Founded
  • FNF 1847
  • UTHR 1996
  • Country
  • FNF United States
  • UTHR United States
  • Employees
  • FNF N/A
  • UTHR N/A
  • Industry
  • FNF Specialty Insurers
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • FNF Finance
  • UTHR Health Care
  • Exchange
  • FNF Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • FNF 17.8B
  • UTHR 14.4B
  • IPO Year
  • FNF N/A
  • UTHR 1999
  • Fundamental
  • Price
  • FNF $54.72
  • UTHR $318.85
  • Analyst Decision
  • FNF Strong Buy
  • UTHR Buy
  • Analyst Count
  • FNF 5
  • UTHR 12
  • Target Price
  • FNF $71.60
  • UTHR $392.00
  • AVG Volume (30 Days)
  • FNF 1.5M
  • UTHR 477.3K
  • Earning Date
  • FNF 05-07-2025
  • UTHR 04-30-2025
  • Dividend Yield
  • FNF 3.65%
  • UTHR N/A
  • EPS Growth
  • FNF 32.86
  • UTHR 18.86
  • EPS
  • FNF 4.04
  • UTHR 25.10
  • Revenue
  • FNF $13,166,000,000.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • FNF $1.39
  • UTHR $14.37
  • Revenue Next Year
  • FNF $13.28
  • UTHR $6.05
  • P/E Ratio
  • FNF $13.56
  • UTHR $12.70
  • Revenue Growth
  • FNF 4.42
  • UTHR 19.84
  • 52 Week Low
  • FNF $47.79
  • UTHR $266.98
  • 52 Week High
  • FNF $66.72
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • FNF 35.83
  • UTHR 62.38
  • Support Level
  • FNF $53.43
  • UTHR $311.62
  • Resistance Level
  • FNF $54.45
  • UTHR $320.91
  • Average True Range (ATR)
  • FNF 1.06
  • UTHR 7.20
  • MACD
  • FNF -0.25
  • UTHR 1.57
  • Stochastic Oscillator
  • FNF 28.45
  • UTHR 92.72

About FNF FNF Group of Fidelity National Financial Inc.

Fidelity National Financial Inc provides title insurance, escrow, and other title-related services. It operates in three segments: Title, F&G, Corporate and Other. The title segment that derives the majority of revenue consists of the operations of title insurance underwriters and related businesses, which provide title insurance and escrow and other title-related services including trust activities, trustee sales guarantees, and home warranty products. Substantially all of the company's revenue is generated in the United States.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: